CD326 (EpCAM) Monoclonal Antibody (G8.8), Super Bright™ 600, eBioscience™, Invitrogen™

Description

Description: The G8.8 monoclonal antibody reacts with the 40 kDa mouse EpCAM (epithelial cellular adhesion molecule), also known as EGP40 (epithelial glycoprotein 40), 17-1A antigen, TACSTD1 (tumor-associated calcium signal transducer 1), and CD326. The immunogen used to generate the G8.8 antibody was the TE-71 thymic epithelial cell line. CD326 is expressed on the majority of epithelial cells, and is considered a pan-carcinoma antigen. CD326 mediates calcium-independent, homophilic, cell-cell adhesion and may function as a growth factor receptor. The antigen is being used as a target for immunotherapy treatment of human carcinomas. CD326 binds LAIR-1 (CD305) and LAIR-2 (CD306) to inhibit cellular activation and inflammation. This epithelial glycoprotein is now recognized as having an important role in tumor biology. Applications Reported: This G8.8 antibody has been reported for use in flow cytometric analysis. Applications Tested: This G8.8 antibody has been tested by flow cytometric analysis of TE-71 cell line. This may be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.